[625,000% Gain] – Are You Ready for the Next Altcoin Boom?

All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you know anything about crypto, you know that altcoin seasons are where some of the biggest gains happen.

Diane Gerst Biography and Net Worth

Director of Amphastar Pharmaceuticals

Diane G. Gerst was the Company’s Executive Vice President of Quality Assurance and Regulatory Affairs until February 2018 and served as the President of Amphastar Nanjing Pharmaceuticals Inc., one of the Company’s subsidiaries, from March 2014 until February 2018. From August 2013 to June 2015, Ms. Gerst served as the Company’s Corporate Senior Vice President of Quality Assurance. Ms. Gerst served as Corporate Vice President of Quality Assurance from August 2003 until her promotion to Senior Vice President in August 2013. Previously, she was the Company’s Vice President of Regulatory Affairs from June 2001 to July 2002. Before joining the Company, Ms. Gerst held various management-level positions in regulatory and quality, including eight years at Braun-McGaw and seven years at IMS. Ms. Gerst received a B.A. from the University of California, Berkeley. Ms. Gerst achieved the National Association of Corporate Directors Directorship Certification (NACD.DC) in November 2021.

What is Diane G. Gerst's net worth?: The estimated net worth of Diane G. Gerst is at least $575,321.60 as of July 18th, 2022. Ms. Gerst owns 12,842 shares of Amphastar Pharmaceuticals stock worth more than $575,322 as of December 3rd. This net worth estimate does not reflect any other assets that Ms. Gerst may own. Learn More about Diane G. Gerst's net worth.
How do I contact Diane G. Gerst?: The corporate mailing address for Ms. Gerst and other Amphastar Pharmaceuticals executives is 11570 SIXTH STREET, RANCHO CUCAMONGA CA, 91730. Amphastar Pharmaceuticals can also be reached via phone at (909) 980-9484 and via email at [email protected]. Learn More on Diane G. Gerst's contact information.
Has Diane G. Gerst been buying or selling shares of Amphastar Pharmaceuticals?: Diane G. Gerst has not been actively trading shares of Amphastar Pharmaceuticals in the last ninety days. Most recently, Diane G. Gerst sold 1,520 shares of the business's stock in a transaction on Monday, July 18th. The shares were sold at an average price of $37.23, for a transaction totalling $56,589.60. Following the completion of the sale, the director now directly owns 12,842 shares of the company's stock, valued at $478,107.66. Learn More on Diane G. Gerst's trading history.
Who are Amphastar Pharmaceuticals' active insiders?: Amphastar Pharmaceuticals' insider roster includes Diane Gerst (Director), Richard Koo (Director), Howard Lee (Director), Yakob Liawatidewi (EVP), Mary Luo (COO), Ziping Luo (Chairman), William Peters (CFO), Floyd Petersen (Director), Richard Prins (Director), Michael Zasloff (Director), Jack Zhang (CEO), Yongfeng Zhang (Co-Founder), and Rong Zhou (EVP). Learn More on Amphastar Pharmaceuticals' active insiders.
Are insiders buying or selling shares of Amphastar Pharmaceuticals?: In the last year, insiders at the sold shares 20 times. They sold a total of 349,556 shares worth more than $19,025,420.83. The most recent insider tranaction occured on November, 12th when EVP Rong Zhou sold 6,893 shares worth more than $336,929.84. Insiders at Amphastar Pharmaceuticals own 27.1% of the company. Learn More about insider trades at Amphastar Pharmaceuticals.
Information on this page was last updated on 11/12/2024.

Diane G. Gerst Insider Trading History at Amphastar Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
7/18/2022	Sell	1,520	$37.23	$56,589.60	12,842
7/11/2022	Sell	1,521	$36.26	$55,151.46	12,842
7/5/2022	Sell	1,813	$35.00	$63,455.00	12,842
12/19/2017	Sell	523	$19.48	$10,188.04	30,164
12/12/2017	Sell	523	$18.96	$9,916.08	30,687
11/28/2017	Sell	523	$18.15	$9,492.45	31,210
11/21/2017	Sell	523	$18.81	$9,837.63	31,733
11/15/2017	Sell	523	$17.77	$9,293.71	32,256
11/7/2017	Sell	523	$17.93	$9,377.39	32,779
10/24/2017	Sell	523	$18.29	$9,565.67	33,302
10/17/2017	Sell	523	$18.48	$9,665.04	33,825
10/5/2017	Sell	8,444	$18.87	$159,338.28
12/15/2016	Sell	2,940	$20.51	$60,299.40	26,195
8/19/2016	Sell	24,046	$19.28	$463,606.88	39,031
5/18/2016	Sell	1,427	$13.97	$19,935.19	28,649
4/19/2016	Sell	21,244	$12.89	$273,835.16	39,713
4/18/2016	Sell	15,637	$12.83	$200,622.71	39,713
4/8/2015	Sell	10,000	$15.79	$157,900.00

Diane G. Gerst Buying and Selling Activity at Amphastar Pharmaceuticals

Amphastar Pharmaceuticals Company Overview

Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency. The company provides Amphadase, an injection to absorb and disperse other injected drugs; Epinephrine injection for allergic reactions; Lidocaine jelly, an anesthetic product for urological procedures; Lidocaine topical solution for various procedures; Phytonadione injection, a vitamin K1 injection for newborn babies; emergency syringe products; morphine injection for use with patient-controlled analgesia pumps; and Lorazepam injection for surgery and medical procedures. In addition, it offers Neostigmine methylsulfate injection to treat myasthenia gravis and to reverse the effects of muscle relaxants; Isoproterenol hydrochloride injection for mild or transient episodes of heart block; Ganirelix Acetate injection for the inhibition of premature luteinizing hormone surges; Vasopressin to increase blood pressure; and Regadenoson, a stress agent for radionuclide myocardial perfusion imaging. Further, the company distributes recombinant human insulin APIs and porcine insulin API. Additionally, it develops generic product candidates, such as injectable, inhalation, and analytical technologies; biosimial product candidates; and intranasal epinephrine for the treatment of allergic reactions. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California.

Today's Range

Now: $44.80

$44.80

$46.11

50 Day Range

MA: $47.78

$43.62

$53.40

2 Week Range

Now: $44.80

$36.56

$65.92

Volume

69,075 shs

Average Volume

397,423 shs

Market Capitalization

$2.15 billion

P/E Ratio

14.93

Dividend Yield

N/A

Beta

0.78